Literature DB >> 35132202

Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases.

Jin Kyung Suh1, Ho Joon Im2, Sung Han Kang3, Hyery Kim3, Eun Seok Choi3, Kyung-Nam Koh3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35132202     DOI： 10.1038/s41409-021-01556-8

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  6 in total

1.  Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities.

Authors:  Brigit Greystoke; Sonia Bonanomi; Trevor F Carr; Maged Gharib; Tasneem Khalid; Mary Coussons; Mamta Jagani; Paru Naik; Kanchana Rao; Nicholas Goulden; Persis Amrolia; Robert F Wynn; Paul A Veys
Journal:  Br J Haematol       Date:  2008-05-19       Impact factor: 6.998

2.  Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.

Authors:  Yael Dinur-Schejter; Aviva C Krauss; Odeya Erlich; Natan Gorelik; Anat Yahel; Iris Porat; Michael Weintraub; Jerry Stein; Irina Zaidman; Polina Stepensky
Journal:  Pediatr Blood Cancer       Date:  2014-10-04       Impact factor: 3.167

3.  Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes.

Authors:  Rebecca A Marsh; Kanchan Rao; Prakash Satwani; Kai Lehmberg; Ingo Müller; Dandan Li; Mi-Ok Kim; Alain Fischer; Sylvain Latour; Petr Sedlacek; Vincent Barlogis; Kazuko Hamamoto; Hirokazu Kanegane; Sam Milanovich; David A Margolis; David Dimmock; James Casper; Dorothea N Douglas; Persis J Amrolia; Paul Veys; Ashish R Kumar; Michael B Jordan; Jack J Bleesing; Alexandra H Filipovich
Journal:  Blood       Date:  2012-11-06       Impact factor: 22.113

4.  Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH.

Authors:  Swati Naik; Olive Eckstein; Ghadir Sasa; Helen E Heslop; Robert A Krance; Carl Allen; Caridad Martinez
Journal:  Br J Haematol       Date:  2020-01-27       Impact factor: 6.998

5.  Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan.

Authors:  Shintaro Ono; Tsubasa Okano; Akihiro Hoshino; Masakatsu Yanagimachi; Kazuko Hamamoto; Yozo Nakazawa; Toshihiko Imamura; Masaei Onuma; Hidetaka Niizuma; Yoji Sasahara; Hiroshi Tsujimoto; Taizo Wada; Reiko Kunisaki; Masatoshi Takagi; Kohsuke Imai; Tomohiro Morio; Hirokazu Kanegane
Journal:  J Clin Immunol       Date:  2016-11-04       Impact factor: 8.317

6.  Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.

Authors:  Carl E Allen; Rebecca Marsh; Peter Dawson; Catherine M Bollard; Shalini Shenoy; Philip Roehrs; Rabi Hanna; Lauri Burroughs; Leslie Kean; Julie-An Talano; Kirk R Schultz; Sung-Yun Pai; K Scott Baker; Jeffrey R Andolina; Elizabeth O Stenger; James Connelly; Alyssa Ramirez; Christopher Bryant; Mary Eapen; Michael A Pulsipher
Journal:  Blood       Date:  2018-07-11       Impact factor: 25.476
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.